Niemann-Pick type C (NPC) disease is a rare lysosomal storage disease caused primarily by mutations in NPC1. NPC1 encodes the lysosomal cholesterol transport protein NPC1. The most common NPC1 mutation is a missense mutation (NPC1
Introduction
Niemann-Pick type C disease (NPC, OMIM #257220 and #607625) is a rare [incidence ranging from $1: 89 000 based on projections (1), to 1: 120 000 live births based on clinical observations (2)] fatal neurodegenerative lysosomal storage disease that can manifest from infancy to adulthood depending on the genetic lesion (2, 3) . There are no FDA-approved treatments for NPC, though limited efficacy has been shown for miglustat, a glycosphingolipid synthesis inhibitor, which is approved for use outside the United States. The majority of NPC cases are caused by mutations in NPC1, the gene encoding the transmembrane lysosomal protein NPC1, while a small subset (<5%) are caused by mutations in the NPC2 gene that encodes a luminal lysosomal protein (2) . Both genes encode proteins that are critical for cholesterol egress from lysosomes, though the exact role for each protein in cholesterol transport is not completely understood (4) . While the hallmark of NPC is lysosomal cholesterol accumulation, disease severity depends on the type and position of the mutations in NPC1, as well as the genetic background of the individual (5-7). Most NPC patients have compound heterozygous NPC1 mutations, and the most common mutation, NPC1 I1061T , typically leads to a juvenile disease onset and results in a misfolded protein that is rapidly degraded by the proteostasis machinery (5, 8, 9) .
Previous studies identified HDAC inhibitors (HDACi) as negative modulators of lysosomal cholesterol storage (10) , possibly through modulation of the proteostasis machinery (10) . Earlystage clinical investigation of the HDACi, vorinostat (SAHA) is currently underway. Another drug proposed to modulate proteostasis, arimoclomol, is being tested in a phase III clinical trial for treatment of NPC1 patients (11) . Finally, the cholesterolreducing agent, 2-hydroxypropyl-ß-cyclodextrin (HPBCD), has shown efficacy in treatment of NPC1 patients a phase 1/2a trial (12) , and is now in a pivotal phase 3 trial. Though promising, each therapy is associated with distinct off-target or adverse side effects, or limited blood-brain barrier permeability (13) (14) (15) , the latter requiring direct delivery into the central nervous system (12, 16) . Further, although HDACi and arimoclomol are hypothesized to modulate the general chaperone machinery (10) , neither of these drugs nor HPBCD directly addresses the protein misfolding defect present in the majority of NPC patients harboring missense mutations (17) . Thus, there remains an unmet clinical need for more specific therapies that target the underlying molecular defect.
A number of large-scale compound screens designed to identify an effective NPC therapeutic have been reported. Screening strategies have varied. Early attempts utilized automated microscopy of NPC1 mutant CHO cells stained with the fluorescent cholesterol dye, filipin (18, 19) , while more recent screens have used fluorescent plate reader-based assays on patient-derived fibroblasts in conjunction with the acidophilic dye, lysotracker, to label acidic organelles such as late endosomes and lysosomes (20) . Lysotracker staining is increased in both NPC patient fibroblasts and fibroblasts from other lysosomal storage disease patients relative to fibroblasts from healthy individuals, making it a useful screening reagent (20) . Still others have utilized mutant cells from an Npc1 knockout mouse model (21) . However, none of the previously described screens has considered lysosomal cholesterol content in NPC patient cells as a first-tier screen in a high-content fluorescent microscopy assay.
By examining both cholesterol content and lysosomes in patient cells using the dual markers filipin and anti-LAMP1, a lysosome/late endosome-specific marker, increased specificity is achieved. Moreover, a high-content phenotypic assay in patient-derived cells improves clinical relevance and reveals information about cell health and viability in response to test compounds, and has increased sensitivity and power compared to plate reader-based assays. In this report, we describe a highcontent screen, based on filipin and LAMP1 readouts, of NPC patient fibroblasts. NPC patient fibroblasts homozygous for the most common NPC1 mutation, NPC1
I1061T (5, 8) were selected as a cell source given the prevalence of the mutation, the moderate degree of lysosomal cholesterol accumulation, and the potential to correct the protein misfolding phenotype with a proteostasis modulator (9) . Using this assay, we screened 3532 small molecules, primarily FDA-approved drugs and well-characterized tool compounds that modulate known targets, affording opportunities for drug repurposing, and identification of specific molecular pathways and targets that impact the cellular phenotype. Among the hits identified were previously described modulators of NPC cholesterol accumulation as well as novel modulators.
Results
Development of a high-content image-based assay for lysosomal cholesterol accumulation in NPC patient cells
To develop a miniaturized high-content image-based assay in 384-well plates for monitoring lysosomal cholesterol accumulation, a panel of control and NPC patient cells representing a range of NPC1 genotypes was assembled (Table 1) . These included fibroblasts from two patients homozygous for the most common NPC mutation, NPC1 I1061T (5, 8) and a severely affected patient with a compound heterozygous mutation (NPC1 E612D/542fsX ) (3). We first sought to validate the sensitivity and relevance of our assays by confirming the cellular phenotypes of the control and NPC patient cells. In addition, we aimed to determine the extent to which genotype and clinical phenotype correlate with cellular phenotype in our proposed system and the dynamic range of our assay. To that end, NPC patient lines, and two control fibroblast lines from unaffected individuals, were cultured in 384-well imaging plates, and characterized in parallel for cholesterol content, with the naturally fluorescent polyene antibiotic, filipin (19) and for lysosomes with lysotracker dye or by LAMP1 immunofluorescence as described in Supplementary Material, Figure S1 .
We observed a clear phenotypic spectrum for cholesterol content and lysosomal staining (Fig. 1) . As observed in the literature (20) , NPC1 patient cells had increased lysosomal signal, as inferred from LAMP1 staining, and cholesterol accumulation, based on filipin, compared with control cells, with GM18436 NPC1 E612D/542fsX patient cells exhibiting higher levels than NPC1 I1061T cells (Fig. 1) . Notably, of the two fibroblast lines, GM18453 and GM18417, which harbor identical NPC1 mutations (NPC1 I1061T/I1061T ), GM18453 had a more pronounced phenotype ( Fig. 1) . Likewise, we observed variations in both filipin and lysotracker for control lines (Fig. 1) , underscoring the importance of examining multiple patient and control lines, as modifier genes and epigenetic factors can impact phenotypes (5-7). Of the two NPC1 I1061T patient lines, GM18453, which exhibited a stronger lysosomal cholesterol phenotype, was selected for further assay development and screening with the expectation that it should be amenable to rescue by proteostatic regulators as well as other molecular modulators. HDACi are capable of ameliorating NPC patient cell lysosomal cholesterol storage, possibly through regulation of the proteostasis machinery (10) . We tested the potent HDACi, trichostatin A (TSA) and panobinostat (Pb, LBH589) in our assay and found a robust reduction in lysosomal cholesterol content following 72 h treatment (Supplementary Material, Fig. S2A and B). HDACi treatment led to a reduction in cell number compared to DMSO-treated cells, likely due to both cytotoxicity and anti-proliferative effects of HDACi (22) , but remaining cells appeared healthy according to nuclear parameters (Supplementary Material, Fig. S2C and D and data not shown). Taken together these data suggest that HDACi's effects on lysosomal cholesterol are separable from its cytotoxicity. SSMD (strictly standardized mean difference) and Z 0 values for screening were found to be acceptable for screening (23) , with panobinostat exhibiting the most robust and reproducible effect on both filipin and LAMP1 immunofluorescence staining (Supplementary Material, Fig. S2A and B). Both SSMD and Z 0 values provide information regarding effect size in screens; however, SSMD is more suitable for assessing quality control for strong or moderate effect differences compared to Z 0 , which is better suited to extremely strong effect differences (24) . Therefore, SSMD was employed going forward for quality control assessment. Based on these results, GM18453 (NPC1 I1061T/
I1061T
) patient fibroblasts and the control compound, panobinostat, were selected for a subsequent pilot screen.
To test the robustness of our assay on a smaller scale before screening a larger library, and to determine optimal timing of compound exposure, we performed a pilot screen of a kinase inhibitor library comprised of 327 well-annotated small molecule kinase inhibitors. The library was screened in duplicate at 5 lM, with 32 positive control wells and 32 negative control wells per plate (16 wells per side of plate). Parallel experiments were run at 48 and 72 h of exposure to compound. Although statistically significant decreases in both filipin and LAMP1 were observed at 48 h (Supplementary Material, Fig. S3) , SSMD values were greater at 72 h (for filipin: 48 h, SSMD ¼ À1.45, 72 h SSMD ¼ À3.04). Of 327 compounds tested, 13 (4.0%) were cytotoxic based on cell counts. A compound was considered cytotoxic at a Z-score À5 for number of nuclei. A Z-score of À5 was chosen based on average Z-scores for the positive control, panobinostat, since HDACi are known to exhibit cytotoxic and antiproliferative effects (22) . Compounds were then filtered for antibiotic, filipin [3] . Lysosomal morphology (size, distribution) was assessed using lysotracker-red. 20Â magnification. Scale bar ¼ 50 lM. Error bars: Mean 6 SD, n ¼ 3 wells/condition.*P < 0.05 versus Control I, **P < 0.01 versus Control I, $P < 0.05 versus Control II, one-way ANOVA followed by Tukey's test.
hits that reduced filipin and LAMP1 without drastically affecting nuclear roundness (duplicate Z-score 3.5), intensity (À2.0 duplicate Z-score 2.0), or size (duplicate Z-score ! À2.0). A Z-score threshold of À2.0 was initially selected in order to identify compounds that fall outside of 95% of results in a normal distribution. This cut-off was then adjusted (e.g. nuclear roundness) to increase the number of hits for further characterization.
Of the remaining non-toxic compounds, 50/327 (15.3%) decreased filipin (duplicate Z-score À2) at 72 h, and 10/327 (3.1%) decreased LAMP1 (Z-score < À2.5 singleton as no compounds decreased LAMP1 in duplicate) but only four (1.2%) decreased both LAMP1 and filipin. These four represented three unique compounds: staurosporine (duplicate compounds were present in the library), the GSK3b inhibitor TWS-119, and MK-2 Inhibitor III (Table 2 , Supplementary Material, Fig. S4 and data not shown). Thus, having demonstrated in our pilot screen that using filipin and LAMP1 as multiplexed readouts was an efficient approach that aided in hit detection and classification, we extended our screening efforts to larger compound collections described below.
High-content screen for modifiers of lysosomal cholesterol in NPC patient cells
In an effort to identify a clinically tractable mediator of lysosomal cholesterol storage in NPC patient cells, a library of 2013 FDAapproved compounds was screened in duplicate using the dual LAMP1/filipin assay. In addition, we screened our assay against a collection of 260 compounds with epigenetic activity, 45 compounds with proteostatic activity, 760 human metabolites (25) and 127 compounds that target metabolic pathways (Table 2) . Due to redundancy in the libraries, in total 3248 unique compounds were screened (Supplementary Material, Table S1 ). Average SSMD between DMSO and panobinostat-treated groups were À3.15 (filipin) and À3.39 (LAMP1) (26) . Average coefficient of variation (CV) for DMSO and panobinostat-treated groups were 7.11% (filipin) and 5.89% (LAMP1) ( Table 2) .
Seventy-five (2.1%) compounds were cytotoxic based on number of nuclei. Our criterion for hit selection was Z-score-À2 in duplicate for both filipin and LAMP1 staining intensity. For initial hit selection, we considered compounds with evidence of cytotoxicity (either by nuclei number or morphology) given the high concentration at which compounds were screened and the small number of hits. From the primary screen, 171 compounds decreased filipin and 160 compounds decreased LAMP1 (Table 2 , Supplementary Material, Table S1 ). Only 47 filipin hits (27%) were also LAMP1 hits (Table 2) , an overall hit rate of 1.3%. The observed difference between filipin and LAMP1 hits may be related to differential flux rates for LAMP1 protein and cholesterol. Three of the 47 hits with decreases in both LAMP1 and filipin were cytotoxic based on number of nuclei. However, decreased lysosomal cholesterol was not generally correlated with cytotoxicity, as 68/75 (91%) of the cytotoxic compounds we identified did not exhibit decreases in both LAMP1 and filipin. Dose-response studies identified one compound, alexidine dihydrochloride (alexidine) as having dosedependent activity, with half-maximal inhibitory concentrations (IC50) of 4.3 lM for 6.36 lM for LAMP1 and filipin readouts, respectively ( Fig. 2A and B) . Although alexidine was cytotoxic at the original dose screened (5 lM), its effect on lysosomal cholesterol storage was separable from cytotoxicity as indicated by nuclear measures (Fig. 2C ) and cell area (Fig. 2D) . Consistent with other reports (27), we did not identify any of the six statins included in our repurposing library as hits (Supplementary Material, Fig. S5 ).
Alexidine is a novel enhancer of lysosomal cholesterol release through upregulation of NPC1-and NPC2-dependent and -independent pathways Alexidine was then tested in secondary assays to determine whether the compound directly affected NPC1 expression. Western blot analysis revealed a $3-fold increase in NPC1 protein expression following 72 h treatment in both control and NPC1 mutant cells (NPC1 I1061T/I1061T ) ( Fig. 3A and B) . We did not observe an increase in NPC1 protein expression following 72 h HDACi (panobinostat) treatment (Fig. 3A and B) , although HDACi treatment was effective as evidenced by robust induction of acetylated tubulin (Fig. 3C) .
The NPC1 I1061T missense mutation leads to rapid proteasomal degradation of immature NPC1 (9) . Forced expression of NPC1-mutant protein allows some protein to escape the degradation pathway, resulting in increased delivery of mature, fully glycosylated mutant protein to the endosome/lysosome where NPC1 functions in lysosomal cholesterol trafficking (9) . To assess the maturity of the increased NPC1 protein following alexidine treatment ( Fig. 3A and B) , we performed Endoglycosidase H (EndoH) digestion to remove immature N-linked glycan residues. Resistance to EndoH is indicative of protein trafficking beyond the endoplasmic reticulum in the secretory pathway. EndoH digestion revealed a dose-dependent increase in both EndoH-sensitive (immature) and EndoH-resistant (mature) NPC1 populations in alexidine-treated NPC1 I1061T/I1061T fibroblasts, as well as an increase in EndoH-resistant NPC1 in alexidine-treated control fibroblasts ( Fig. 3C and D) .
qRT-PCR analysis of NPC1 transcript expression revealed that the alexidine-mediated change in NPC1 protein expression was accompanied by NPC1 gene expression changes (Fig. 3E ). NPC1 transcript abundance was similar in vehicle-treated cells from control and mutant NPC1 cell lines, a finding that is in agreement with previously published studies (9) .
To determine whether alexidine acts in an NPC1-or NPC2-dependent manner, alexidine-mediated reduction of lysosomal cholesterol was next tested in control cells, and null mutant NPC1 À/À and NPC2 À/À cells (Table 1) . Alexidine-reduced lysosomal cholesterol in control cells to a similar extent to NPC1
I1061T/ I1061T patient cells, and to a lesser extent in NPC1 À/À and NPC2 À/À cells (e.g. reduction in LAMP1 DMSO versus alexidine:
( Fig. 4A-C ). At the concentrations tested, alexidine was not cytotoxic, based on cell number, providing further evidence that alexidine's effects on lysosomal cholesterol can be separated from its cytoxicity (Supplementary Material, Fig. S6 ). Thus, alexidine enhances both NPC1-and NPC2-dependent and -independent cholesterol release. Finally, in an effort to understand the functional consequences of the observed alexidine-mediated NPC1 gene and protein expression changes, we performed LDL-stimulated cholesterol esterification assessments in alexidine-treated control and patient cells. To directly analyze the fate of lysosomal cholesterol, LDL was reconstituted with deuterated cholesteryl ester. We found an increase in esterification of LDL-derived cholesterol in
NPC1
I1061T/I1061T patient cells treated with alexidine ( Fig. 5A-E ).
Increased esterification of non-deuterated cholesterol was also observed, suggesting trafficking of non-LDL-derived cholesterol to the endoplasmic reticulum was also enhanced. These data provide direct evidence for improved lysosomal cholesterol export following alexidine treatment. In support of this interpretation, we also found corresponding changes in gene expression related to improved cholesterol trafficking ( Fig. 5F-H) . We assayed by qRT-PCR expression of several genes known to be modulated by cholesterol movement from the lysosome. Alexidine reduced expression of sterol regulatory elementbinding protein (SREBP2)-dependent targets like the cholesterol uptake transporter, LDLR and the cholesterol biosynthetic gene, HMGCR (28), similar to HDACi treatment in both control and patient cells (Fig. 5F and G) . In addition, expression of the LXRdependent cholesterol export gene, ABCA1 (29), was induced in alexidine-treated control and patient cells (Fig. 5H) .
Discussion
We developed a phenotypic NPC patient cell-based assay for inhibitors of lysosomal cholesterol, employing tandem use of filipin and LAMP1 assays which aided in hit selection (Table 2) without substantially increasing assay time or labor input for this focused screen. We tested this assay in multiple control and patient lines and demonstrated in a high-throughput screen its utility for reproducibly identifying compounds that modulate levels of lysosomal cholesterol, including a novel lysosomal cholesterol-reducing molecule, alexidine. Alexidine is an antibacterial bisbiguanide found in antimicrobial mouthwashes and contact lens solutions. Alexidine binds to bacterial lipopolysaccharides (LPS) and phospholipids and disrupts membranes by producing lipid phase separation and domain formation (30, 31) . In addition, alexidine has been demonstrated to affect metabolism in hematopoietic stem cells through activation of AMPK (32) . Our data indicate that alexidine affects multiple cellular and molecular processes in control and NPC patient fibroblasts to reduce lysosomal cholesterol. Alexidine induces transcription of NPC1 (Fig. 3E ) and in turn increases total NPC1 protein ( Fig. 3A and B) as well as mature, EndoH-resistant NPC1 protein glycoforms ( Fig. 3C and D) . Increased mature NPC1 likely helps facilitate lysosomal cholesterol export (Fig. 5A-E) , especially in NPC1 I1061T patient cells where misfolded NPC1 I1061T is rapidly degraded in the endoplasmic reticulum prior to processing in the Golgi and trafficking to the lysosome (9).
Not only does alexidine increase NPC1 expression, but it also affects expression of genes critical for cholesterol flux. Alexidine inhibits expression of SREBP2 targets that regulate cholesterol uptake and biosynthesis (28) while inducing expression of a key LXR target that regulates cholesterol export (29) (Fig. 5F-H) . Alexidine may directly affect expression of cholesterol flux genes. More likely, these gene expression changes may result from the alexidine-mediated improvement in cholesterol trafficking in NPC patient cells, promoting increased cholesterol trafficking to mitochondria and conversion of cholesterol to oxysterol LXR ligands. The latter mechanism could explain the NPC1-and NPC2-independent reduction in lysosomal cholesterol observed in NPC1 À/À and NPC2 À/À cells. It is also possible that the NPC1/2-independent effect of alexidine on cholesterol storage may be mediated through activation of AMPK (32, 33) . Although alexidine demonstrated efficacy in NPC1 À/À and NPC2 À/À cells, the effect on lysosomal cholesterol reduction was blunted compared with control or NPC1 I1061T cells (Fig. 4) , suggesting that both NPC1 and NPC2 are required for full alexidine efficacy. Forced overexpression of NPC1 was reported to contribute to phenotypic improvement in NPC1
I1061T patient cells. It has been noted, for example, that transfection with an NPC1 I1061T DNA construct is sufficient to rescue NPC1-mutant cells by forcing an adequate amount of mutant NPC1 to bypass the endoplasmic reticulum proteostasis control machinery (9). Since we observed a similar effect on lysosomal cholesterol accumulation in control cells and on NPC1 expression in patient cells, we hypothesize that the activity of alexidine was unlikely specific to the stabilization of misfolded-mutant NPC1. EndoH studies support this hypothesis as both EndoH-sensitive and EndoH-resistant pools of NPC1 I1061T were increased in patient cells following alexidine treatment (Fig. 3C and D) . This is further supported by an earlier study demonstrating that $50% of normal NPC1 protein is degraded within the ER (9) . The utility of a compound like alexidine for inducing NPC1 expression and maturation has been repeatedly explored using other approaches. HDACi have been shown to affect the proteostatic machinery in other lysosomal storage disease settings (34) and have demonstrated efficacy in decreasing lysosomal cholesterol storage for multiple different NPC1 patient mutations (17) . This supports the hypothesis that HDACi modulate endoplasmic reticulum-associated degradation factors to allow more mutant NPC1 to reach the lysosome and improve cholesterol trafficking. Along similar lines arimoclomol is thought to act as a co-inducer, along with cellular stress, to upregulate the chaperone, HSP70 (11) . Additional work by Ohgane et al. confirms the usefulness of a chaperone-based approach for improving the cholesterol storage defect of NPC patient cells (35) . In this case, oxysterol derivatives were capable of binding and stabilizing mutant NPC1, thereby increasing expression and localization to the lysosome (35) . Alternatively, the NPC1-binding fibroblasts were treated with DMSO (0.05%), 122 nM alexidine, or 1.1 lM alexidine for 72 h and then fixed, stained with filipin and anti-LAMP1 and imaged. Quantification of filipin (A) and LAMP1 (B) and representative images of treated cells (C). Scale bar ¼ 50 lM. Bars: mean 6 SD, n ¼ 4 wells/condition, ****P < 0.0001, ***P < 0.001, **P < 0.01 versus genotype-matched DMSO, alexidine two-way ANOVA followed by Dunnett's test.
protein TMEM97 was shown to be a negative regulator of NPC1 expression, making inhibition of TMEM97 an attractive, yet underexplored NPC therapeutic angle (36) .
An alternate screening strategy, though technically challenging, might require assessment of the ratio of glycosylated, mature NPC1 relative to total cellular NPC1. NPC1 expressioninducing compounds like alexidine should increase total NPC1 expression (Fig. 3A) and moderately increase glycosylated NPC1, but a true NPC1 chaperone would likely robustly increase both, with the glycosylated fraction becoming the predominant species, as in control cells (Fig. 3C and D) . This outcome could be screened against using NPC1 antibodies specific to immature and mature NPC1. To our knowledge, such reagents are not currently available. Another possible screening strategy raised by our findings is a transcription-based readout of endogenous NPC1. Although this approach would not enrich for mutant condition, ****P < 0.0001 versus DMSO, one-way ANOVA followed by Dunnett's test. (F-H) Alexidine treatment modifies expression of cholesterol flux genes. Gene expression by TaqMan qRT-PCR in indicated cell lines following 48 h alexidine (3 lM) treatment. n ¼ 3 biological replicates, mean 6 SD, ****P < 0.0001, **P < 0.01, *P < 0.05 versus genotype-DMSO (two-way ANOVA followed by Dunnett's test).
NPC1 chaperones, transcriptional activators for other protein misfolding diseases like Cystic Fibrosis have proved successful in preclinical studies (37) . In summary, we developed a sensitive high-throughput phenotypic screening assay for NPC patient fibroblasts sensitive to multiple genotypes and degrees of phenotypic severity. Based on a dual readout of lysosomal cholesterol, we screened $3500 compounds, including 2013 FDA-approved drugs and an additional $1500 bioactive compounds against NPC1
I1061T patient cells. A number of HDACi, a class of compounds identified previously as modulators of cholesterol levels in NPC1 patient cells, were identified as hits. Of the non-HDACi hits, the strongest hit, alexidine, was confirmed as an inducer of both total and mature NPC1 protein expression that also modulates expression of genes critical for cholesterol flux, but is unlikely to act as a chaperone for misfolded NPC1
I1061T
. Although unsuitable for systemic therapy, alexidine has utility as a tool compound for further NPC studies and as a potent inducer of NPC1. Thus, our screen successfully identified alexidine as a novel enhancer of lysosomal cholesterol release through upregulation of NPC1-and NPC2-dependent and -independent pathways. These data demonstrate that this phenotypic assay has the capability to identify hits representing diverse molecular mechanisms that modulate cholesterol accumulation in NPC1-mutant cells, motivating extension to larger screens of more diverse compound collections.
Materials and Methods

Cell culture
NPC patient fibroblasts were obtained from the Coriell Institute for Medical Research (Camden, NJ) (Table 1) . Control, normal human fibroblasts were obtained from Lonza (Allendale, NJ). 
Image acquisition and analysis
Following filipin/LAMP1 staining, cells were immediately imaged with a Perkin-Elmer Opera Phenix or QEHS (Waltham, MA) highcontent automatic imaging system with a 20Â air objective in confocal mode. Due to field size differences, five fields per well were imaged for each experiment analyzed with the QEHS and two fields per well were imaged for each experiment analyzed on the Opera Phenix such that >200 cells were analyzed from each well. Images were analyzed on a per cell basis and then values were averaged across all cells and all fields acquired for each well. Images were analyzed and quantified using Perkin-Elmer Harmony V R image analysis software (Supplementary Material, Fig. S1 ). Using Perkin Elmer's proprietary image analysis tools, cells were segmented first by identifying nuclei ('Find Nuclei' building block) (Supplementary Material, Fig. S1C ), and then surrounding cytoplasmic area ('Find Cytoplasm' building block) (Supplementary Material, Fig. S1D ). To determine cell health, cell number was determined along with three nuclear parameters: nuclear roundness, area, and staining intensity ('Calculate Morpholopgy Properties') ( Supplementary Material, Fig. S1E ). Mean cytoplasmic LAMP1 and filipin intensities ('Calculate Intensity Properties' building block) were then measured in the segmented cytoplasm (Supplementary Material, Fig. S1F and G) such that the intensity of each was normalized to total cell area on a per cell basis. No background correction was performed, however the cell segmentation algorithm was adjusted and validated for individual plates to account for staining differences between experiments. Cell number was counted for each well and compared with the average for control wells by Z-score to determine cytotoxicity.
Gene expression
Fibroblasts were plated on 60 mm dishes (250 000 cells/dish) and treated with compounds for 48 h. RNA was isolated from fibroblasts using the Qiagen RNeasy Kit (74104, Hilden, Germany). A total 8.5 ng of RNA per target probe were added to the Taqman RNA to CT 1 step kit (Applied Biosystems, 4392938, Foster City, CA) with the appropriate Taqman probe (Applied Biosystems, 4331182) (GAPDH: _g1, NPC1: Hs00264835_m1, ABCA1: Hs01059137_m1, LDLR: Hs01092524_m1, HMGCR: Hs00168352_m1). Gene expression analysis was performed using a ViiA TM 7 Real-Time PCR System (Thermo Fisher, Waltham, MA) using the 2-D(DCT) method.
Western blot
Fibroblasts (250 000/plate) were plated and treated with compounds for 72 h. Cells were lysed in 1Â RIPA buffer (Cell Signaling Technologies, 9806S, Danvers, MA) with 1Â protease inhibitors (Roche, 11836170001, Basel, Switzerland) and protein was quantified using Bio-Rad DC Protein Assay (5000112, Hercules, CA). A total of 20 lg of lysate were resolved on a 4-12% Bis/Tris NuPage protein gel (Thermo Fisher, NP0322PK2) and transfered to a nitrocellulose membrane (Thermo Fisher, LC2006). Membranes were probed for b-Actin 1: 10 000 (Sigma, A5441), NPC1 1: 1000 (in-house antibody, Ory Laboratory, St. Louis, MO) (40) , and acetylated Tubulin 1: 5000 (Sigma, T7451) diluted in 5% non-fat milk.
EndoH assay
On day 0, NPC1 I1061T/I1061T or normal human skin fibroblasts were plated in 2 ml culturing media at 1 Â 10 5 or 0.5 Â 10 5 cells/ well in a 6-well dish, respectively. On day 1, 1 ml of media was removed and replaced with 1 ml complete media containing Alexidine or DMSO vehicle. On day 4, cells were harvested by adding 50 ll RIPA buffer to each well. After 30 min, cell lysate was collected and centrifuged at 18 400g for 20 min at 4 C. The protein concentration of the clarified lysate was determined by BCA assay. A total of 10-20 lg total protein/condition were combined with 1Â glycoprotein denaturing buffer (New England Biolabs) and 1Â GlycoBuffer (New England Biolabs) in water then incubated at 50 C for 30 min. To each tube, 10 000 U/ml Endo Hf (New England Biolabs) or an equal volume of water was added. Samples were incubated overnight at 37 C. Proteins were separated on a 4-12% Bis/Tris gradient gel, transferred to nitrocellulose, then probed for a-tubulin (Sigma, T6199) or NPC1 (40) diluted in 5% non-fat milk.
Esterification assay
On day 0, NPC1 I1061T/I1061T fibroblasts were plated at 5.8 Â 10 5 cells/10 cm dish. On day 1, media was changed to lipoproteindepleted media with 50 lg/ml LDL reconstituted with deuterated-cholesteryl oleate (d7 CE 18: 1). On day 4, cells were replated at 1.2 Â 10 5 cells/well in a 6-well dish in 2 ml complete media. Once adhered, 1 ml of media was removed and replaced with 1 ml Alexidine treatment media spiked with 10 lL/mL deuterium-labeled oleate (d9 18: 1, Avanti, 861809) complexed to BSA (prepared at 12% in 150 mM NaCl 
Data and statistical analysis
Data are presented as mean 6 standard deviation (SD) unless otherwise stated. Data were evaluated for statistical significance using methods described in figure legends.
Supplementary Material
Supplementary Material is available at HMG online.
